In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors

Enhancing perifosine's anticancer efficacy by preventing autophagy

(2010) Shi-Yong Sun   Autophagy

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

(2010) J. A. Zonder et al.   BLOOD

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lenalidomide down regulates the production of interferon-γ and the expression of inhibitory cytotoxic receptors of human Natural Killer cells

(2010) Nicolas Dauguet et al.   CELLULAR IMMUNOLOGY

First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours

(2010) Clemens Unger et al.   EUROPEAN JOURNAL OF CANCER

Akt inhibitors in clinical development for the treatment of cancer

(2010) Sumanta Kumar Pal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents

(2009) Shuraila F. Zerp et al.   ANTI-CANCER DRUGS

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

(2009) R. Pal et al.   BLOOD

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

(2009) D. Chauhan et al.   BLOOD

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy

(2009) L. Fu et al.   CANCER RESEARCH

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

(2009) M. Ximeri et al.   HAEMATOLOGICA

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

(2009) Constantine S. Mitsiades et al.   SEMINARS IN HEMATOLOGY

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

(2008) Antonia Busse et al.   CANCER

Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro

(2008) M. Schmidt-Hieber et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

(2008) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

(2008) Benjamin L Ebert et al.   PLOS MEDICINE